

1 CAGTGGCGGCGGGTGCAGAAGCCCAAGCAGCGCGGCCGCAGTGGAGGCTAGAGCCGGAGC 60
 -----+-----+-----+-----+-----+-----+-----+
 61 GGCGGCGGCGGCGGCACCCCGGGGAGGTTTAAAGATGGCGGCGGGGGGACAGGGGGCCTG 120
 -----+-----+-----+-----+-----+-----+-----+
 M A A G G T G G L
 121 CGGGAGGAGCAGCGCTATGGGCTGTCGTGCGGACGGCTGGGGCAGGACAACATCACCGTA 180
 -----+-----+-----+-----+-----+-----+-----+
 R E E Q R Y G L S C G R L G Q D N I T V
 181 CTGCATGTGAAGCTCACCGAGACGGCGATCCGGGCGCTCGAGACTTACCAGAGCCACAAG 240
 -----+-----+-----+-----+-----+-----+-----+
 L H V K L T E T A I R A L E T Y Q S H K
 241 AATTTAATTCCTTTTCGACCTTCAATCCAGTTCGAAGGACTCCACGGGCTTGTCAAAATT 300
 -----+-----+-----+-----+-----+-----+-----+
 N L I P F R P S I Q F Q G L H G L V K I
 301 CCCAAAAATGATCCCCTCAATGAAGTTCATAACTTTAACTTTTATTTGTCAAATGTGGGC 360
 -----+-----+-----+-----+-----+-----+-----+
 P K N D P L N E V H N F N F Y L S N V G
 361 AAAGACAACCCTCAGGGCAGCTTTGACTGCATCCAGCAAACATTCTCCAGCTCTGGAGCC 420
 -----+-----+-----+-----+-----+-----+-----+
 K D N P Q G S F D C I Q Q T F S S S G A
 421 TCCAGCTCAATTGCCTGGGATTTATACAAGATAAAATTACAGTGTGTGCAACAAACGAC 480
 -----+-----+-----+-----+-----+-----+-----+
 S Q L N C L G F I Q D K I T V C A T N D
 481 TCGTATCAGATGACACGAGAAAGAATGACCCAGGCAGAGGAGGAATCCCGCAACCGAAGC 540
 -----+-----+-----+-----+-----+-----+-----+
 S Y Q M T R E R M T Q A E E E S R N R S
 541 ACAAAGTTATCAAACCCGGTGGACCATATGTAGGGAAAAGAGTGCAAATTCGGAAAGCA 600
 -----+-----+-----+-----+-----+-----+-----+
 T K V I K P G G P Y V G K R V Q I R K A
 601 CCTCAAGCTGTTTCAGATACAGTTCCTGAGAGGAAAAGGTCAACCCCATGAACCCTGCA 660
 -----+-----+-----+-----+-----+-----+-----+
 P Q A V S D T V P E R K R S T P M N P A
 661 AATACAATTCGAAAGACACATAGCAGCAGCACCATCTCTCAGAGGCCATACAGGGACAGG 720
 -----+-----+-----+-----+-----+-----+-----+
 N T I R K T H S S S T I S Q R P Y R D R
 721 GTGATTCACTTACTGGCCCTGAAGGCCTACAAGAAACCGGAGCTACTTGCTAGACTCCAG 780
 -----+-----+-----+-----+-----+-----+-----+
 V I H L L A L K A Y K K P E L L A R L Q

FIG.1A

Year	1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1960	1961	1962	1963	1964	1965	1966	1967	1968	1969	1970	1971	1972	1973	1974	1975	1976	1977	1978	1979	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	

FIG. 1 B

Appl. No. *To be assigned*; ; Group Art Unit: *To be assigned*;
 Dkt. No. 1488.0880003/EKS/PSC; Inventors: Duan *et al.*;;
 Tel: 202/371-2600; Title: Antibodies Directed to ELL2, a
 New Member of an ELL Family of RNA Polymerase II
 Elongation Factors (As amended herein);

L K R E E E I A K L N N S S P N S S G G
 GTTAAAGAGGATTGCACTGCCTCCATGGAACCTTCAGCAATTGAACTCCCAGATTATTTG
 1621 -----+-----+-----+-----+-----+-----+-----+ 1680
 V K E D C T A S M E P S A I E L P D Y L
 ATAAATATATCGCTATCGTCTCCTATGAGCAACGCCAGAATTATAAGGATGACTTCAAT
 1681 -----+-----+-----+-----+-----+-----+-----+ 1740
 I K Y I A I V S Y E Q R Q N Y K D D F N
 GCAGAGTATGATGAGTACAGAGCTTTGCATGCCAGGATGGAGACTGTAGCTAGAAGATTT
 1741 -----+-----+-----+-----+-----+-----+-----+ 1800
 A E Y D E Y R A L H A R M E T V A R R F
 ATCAAAGTAGATGCACAAAGAAAGCGCCTTTCTCCAGGCTCAAAGAGTATCAGAATGTT
 1801 -----+-----+-----+-----+-----+-----+-----+ 1860
 I K L D A Q R K R L S P G S K E Y Q N V
 CATGAAGAAGTCTTACAAGAATATCAGAAGATAAAGCAGTCTAGTCCCAATTACCATGAA
 1861 -----+-----+-----+-----+-----+-----+-----+ 1920
 H E E V L Q E Y Q K I K Q S S P N Y H E
 GAAAAATACAGATGTGAATATCTTCATAACAAGCTGGCTCACATCAAAGGCTAATAGGT
 1921 -----+-----+-----+-----+-----+-----+-----+ 1980
 E K Y R C E Y L H N K L A H I K R L I G
 GAATTTGACCAACAGCAAGCAGAGTCATGGTCCTAGAACTCTGCTTGGACCAGAAGATGT
 1981 -----+-----+-----+-----+-----+-----+-----+ 2040
 E F D Q Q Q A E S W S *
 GAATAAACTTAAGCTTATTTATTTAAATTCCAAATGAGTTGCTCTAGATTCTAAAAAGG
 2041 -----+-----+-----+-----+-----+-----+-----+ 2100
 TGAAACTTTGGCTGTTGAAAGTTTCAGTATTAGTAACT
 2101 -----+-----+-----+-----+-----+-----+ 2139

FIG.1C

Appl. No. To be assigned; ; Group Art Unit: To be assigned;
 Dkt. No. 1488.0880003/EKS/PSC; Inventors: Duan *et al.*;;
 Tel: 202/371-2600; Title: Antibodies Directed to ELL2, a
 New Member of an ELL Family of RNA Polymerase II
 Elongation Factors (As amended herein);

ELL2	79	mao99tgglreeqrygl scgrrl gqd-nitvl hvkl teta iral ettyqs hknll t pfrps iqf qgl hgl vki t pkn dpl nevh
ELL	75	m-----aalkedrsygl sggrrvsdgskvsvf hvkl tdsairaf esyraqdsvsl rps irf qgsqg hsi t p p dcpae ar
ELL2	159	nfnf ylsnmvckdnpggsf dcii qqt fsssgasql nqlgf i qdk it vcat ndsyqm trermt qae eesr nrs t k v i k p g g p y
ELL	155	tefeyl snl i g r d n p q g s f d c i i q q v y s s h g e v h l d c l g s i q d k i t v c a t d d s y q k a r g s m a q a e e e i r s r s a i v i k a g g r y
ELL2	234	vckrvqi rkapavsd t m p e r k r s t i p m n p a n t i r k t h s s -----s t t s q r p y r d r v i h l l a l k a y k k p e l l a r l o k i d g m n
ELL	235	lgkvvqf rkpapga t d a m p s r k r a t i p i n l a s a i r k s g a s a v s g g s g v s o r p y r d r v i h l l a l r p y r k a e l l r l o k i d g l t
ELL2	311	qkdksn l g a i t l q q v a n l n s k d l s y t l k d y m f k e l q r d w p g y s e i t d r r s l e s v l s r k l n p s q n a t ---g t s r s e s p v c s s r
ELL	315	qadkdal dgil l q q v a n m s a k d g t c t l q d c m y k d v q k d w p g y s e i d d q l l k r v l v r k l c p q d s t g s i l g d p a a s s p p g e r g
ELL2	391	davsspqkrl l d s e f i d p l m n k k a r i i s h l t n r v p p t l n g h l n p t s e k s a a g l p l p p a a a i p t p p p l p s t y l p i s h p p q i
ELL	395	rsasppqkrl qppl f t i d p l a n k k p r i s h f t o r a q p a v n g k l g v p n g r e a l l p t p g p p a s t a t l s s s t h l p p r l e p p r a n d
ELL2	471	vnsn snsp s t p e g n g t q d l p v a s f s a n d s i j y e d q d q k y t s r t s l e t l p p g s v l l k o p k p m e e n h s m s h k s k s k k s k k h k e
ELL	457	p l o d v s n d l g h s g n d c e n g e a a d p a b t v r l g l p -----l l t d c a q p s r p h g s p s r s k p k k s k k h k d
ELL2	551	k d q i k k h d i e e k e e d l k r e e e i q k l n s s p r i s s g g v k e d c t a s m e p s a i e l p d y l i k y i a i v s y e q r q n y k d d f n a e
ELL	532	k e r a a e d k p r a q l p d c a p a t h a t p g a p a d t p g l n g t i c s -----v s s v p t s t s e t p d y l l k y a a i s s s e q r g s y k n d f n a e
ELL2	631	y d e y r a l h a r m e t i m a r r f i k l d a q r k r l s p g s k e y o n v n h e e v l q e y q k i q s s p n y h e e k y r c e y l h n k l a h i k r l i g e f
ELL	612	y s e y r d l h a r i e r i t r r f t i d a q l r q l s o g s e e y e t t r g o i l q e y r k i k k i n t n y s o e k h r c e y l h s k l a h i k r l i a e y
ELL2	640	d q q q a e s i w s
ELL	621	d q r q l q a m p

FIG. 2

Appl. No. To be assigned; ; Group Art Unit: To be assigned;
Dkt. No. 1488.0880003/EKS/PSC; Inventors: Duan *et al.*;;
Tel: 202/371-2600; Title: Antibodies Directed to ELL2, a
New Member of an ELL Family of RNA Polymerase II
Elongation Factors (As amended herein);




FIG. 3

Appl. No. *To be assigned*; ; Group Art Unit: *To be assigned*;
 Dkt. No. 1488.0880003/EKS/PSC; Inventors: Duan *et al.*;;
 Tel: 202/371-2600; Title: Antibodies Directed to ELL2, a
 New Member of an ELL Family of RNA Polymerase II
 Elongation Factors (As amended herein);




FIG. 4

Appl. No. *To be assigned*; ; Group Art Unit: *To be assigned*;
 Dkt. No. 1488.0880003/EKS/PSC; Inventors: Duan *et al.*;;
 Tel: 202/371-2600; Title: Antibodies Directed to ELL2, a
 New Member of an ELL Family of RNA Polymerase II
 Elongation Factors (As amended herein);

-35 Operator 1

AAGCTTAAAAAACTGCAAAAAATAGTTTGACTTGTGAGCGGATAACAAT

-10 Operator 2

50 TAAGATGTACCCCAATTGTGAGCGGATAACAATTTCACACATTAA

S/D

94 ACAGGAGAAATTA CATATG

FIG. 5